C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Top Cited Papers
- 22 September 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (38) , 16157-16162
- https://doi.org/10.1073/pnas.0908201106
Abstract
Screening of phage libraries expressing random peptides for binding to prostate cancer cells primarily yielded peptides that had a C-terminal arginine (or rarely lysine) residue, usually in a consensus context R/KXXR/K. Phage expressing these sequences and synthetic nanoparticles coated with them bound to and were internalized into cells. The C-terminal arginine (or lysine) was essential to the activity; adding another amino acid, or even blocking the free carboxyl group of this arginine residue by amidation, eliminated the binding and internalizing activity. An internal R/KXXR/K can be exposed and switched on by a cleavage by a protease. The strict requirement for C-terminal exposure of the motif prompted us to term the phenomenon the C-end rule (CendR). Affinity chromatography showed that the CendR peptides bind to neuropilin-1 (NRP-1) on the target cells. NRP-1 is a cell-surface receptor that plays an essential role in angiogenesis, regulation of vascular permeability, and the development of the nervous system. VEGF-A165 and other ligands of NRP-1 possess a C-terminal CendR sequence that interacts with the b1 domain of NRP-1 and causes cellular internalization and vascular leakage. Our CendR peptides have similar effects, particularly when made multivalent through coupling to a particle. We also noted a unique and important activity of these peptides: penetration and transportation through tissues. The peptides were able to take payloads up to the nanoparticle size scale deep into extravascular tissue. Our observations have implications in drug delivery and penetration of tissue barriers and tumors.Keywords
This publication has 36 references indexed in Scilit:
- Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factorBlood, 2008
- Molecular Changes in the Vasculature of Injured TissuesThe American Journal of Pathology, 2007
- Structural basis for ligand and heparin binding to neuropilin B domainsProceedings of the National Academy of Sciences, 2007
- Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1Life Sciences, 2006
- Soluble neuropilin targeted to the skin inhibits vascular permeabilityAngiogenesis, 2005
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Role of vascular endothelial growth factor in endometrial vascular events before implantation in ratsReproduction, 2001
- Cysteine-Rich and Basic Domain HIV-1 Tat Peptides Inhibit Angiogenesis and Induce Endothelial Cell ApoptosisBiochemical and Biophysical Research Communications, 2001
- Transport of macromolecules through microvascular wallsCardiovascular Research, 1996